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Abstract
Chronic obstructive pulmonary disease (COPD) is characterised by chronic inflammation of the
airways and progressive destruction of lung parenchyma, a process that in most cases is initiated
by cigarette smoking. Several mechanisms are involved in the development of the disease: influx of
inflammatory cells into the lung (leading to chronic inflammation of the airways), imbalance
between proteolytic and anti-proteolytic activity (resulting in the destruction of healthy lung tissue)
and oxidative stress. Recently, an increasing number of data suggest a fourth important mechanism
involved in the development of COPD: apoptosis of structural cells in the lung might possibly be
an important upstream event in the pathogenesis of COPD. There is an increase in apoptotic
alveolar epithelial and endothelial cells in the lungs of COPD patients. Since this is not
counterbalanced by an increase in proliferation of these structural cells, the net result is
destruction of lung tissue and the development of emphysema. Data from animal models suggest a
role for Vascular Endothelial Growth Factor (VEGF) in the induction of apoptosis of structural cells
in the lung. Other mediators of apoptosis, such as caspase-3 and ceramide, could be interesting
targets to prevent apoptosis and the development of emphysema.
In this review, recent data on the role of apoptosis in COPD from both animal models as well as
from studies on human subjects will be discussed. The aim is to provide an up to date summary on
the increasing knowledge on the role of apoptosis in COPD and pulmonary emphysema.
Review
Chronic Obstructive Pulmonary Disease (COPD) is a
chronic respiratory disease that is associated with an
abnormal inflammatory response of the lungs to noxious
particles or gases (mainly cigarette smoke). This leads to
chronic bronchitis-bronchiolitis (small airways disease)
and/or emphysema that cause airflow limitation that is
not fully reversible. [1]. COPD is the fifth leading cause of
death worldwide, accounting for more than 2 500 000
deaths every year (WHO world health report 2002). More-
over, the prevalence and mortality of COPD are expected
to increase in the coming decades [2].
Several mechanisms contribute to the pathogenesis of
COPD [3]. First, the inhalation of noxious particles such
as cigarette smoke causes the influx of inflammatory cells
into the airways and lungs, leading to chronic inflamma-
tion. Different kinds of inflammatory cells (macrophages,
Published: 30 March 2006
Respiratory Research 2006, 7:53 doi:10.1186/1465-9921-7-53
Received: 13 December 2005
Accepted: 30 March 2006
This article is available from: http://respiratory-research.com/content/7/1/53
© 2006 Demedts et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Respiratory Research 2006, 7:53 http://respiratory-research.com/content/7/1/53
Page 2 of 10
(page number not for citation purposes)
neutrophils, CD8+ T lymphocytes) have been described to
participate in the inflammatory response in the airways of
COPD patients.
Second, there is a disruption of the balance between pro-
teolytic and anti-proteolytic molecules in the lungs of
COPD patients, resulting in an increased proteolytic activ-
ity [4]. This causes the destruction of healthy lung paren-
chyma, which leads to the development of emphysema.
This increase in proteolytic activity may be a consequence
of inflammation (release of proteolytic enzymes by
inflammatory cells such as macrophages and neutrophils)
or may arise from genetic factors (eg alpha-1 antitrypsin
deficiency).
A third mechanism involved in the pathogenesis of COPD
is oxidative stress, which occurs when reactive oxygen spe-
cies are produced in excess of the antioxidant defence
mechanisms [3]. Oxidants are generated in the airways by
cigarette smoking or are released from inflammatory leu-
kocytes and epithelial cells. Oxidative stress can lead to
cell dysfunction or cell death and can induce damage to
the lung extracellular matrix. Moreover, oxidative stress
influences the proteinase-antiproteinase imbalance by
activating proteases and inactivating antiproteinases.
Additionally, oxidants contribute to the inflammatory
reaction by activating the transcription factor NF-κB and
thus inducing the transcription of pro-inflammatory
genes. In conclusion, it is clear that these three processes
(chronic inflammation, proteinase/anti-proteinase imbal-
ance and oxidative stress) involved in the pathogenesis of
COPD are not independent mechanisms and several
interactions between these processes occur during the
development of the disease.
Recent data from both animal models of COPD (Figure 1,
own unpublished observations) as well as from studies in
human subjects suggest that a fourth mechanism might be
involved in the pathogenesis of COPD: disruption of the
balance between apoptosis and replenishment of struc-
tural cells in the lung might contribute to the destruction
of lung tissue in response to cigarette smoke, leading to
emphysema.
Apoptosis
Apoptosis is a tightly regulated mechanism of cell death.
This programmed cell death allows the elimination of
unwanted, damaged or infected cells. At present, three dif-
ferent pathways that are involved in the regulation of
apoptosis have been described (Figure 2). Different cas-
pases (these are proteases with an important function in
the regulation of apoptosis) are involved in these different
pathways [5]. A first pathway is activated in response to
extracellular signals and is mediated by binding of mem-
bers of the tumour necrosis factor family (e.g. Fas ligand,
TNF-α) to death receptors on the cell surface (e.g. Fas,
TNFR). This results in the multimerization of the death
receptor and the formation of the death inducing signal-
ling complex (DISC), containing multiple adaptor mole-
cules such as the Fas associated death domain (FADD).
This FADD interacts with caspase-8. [6,7], leading to the
autolytic activation from pro-caspase-8 to caspase-8. Cas-
pase-8 then activates caspase-3 [8,9], which finally exe-
cutes apoptosis by releasing caspase-activated DNAse
Identification of apoptotic cells in the lung in an animal model of COPD Figure 1
Identification of apoptotic cells in the lung in an animal model of COPD. TUNEL-staining demonstrating an increase 
in apoptotic cells (dark brown nuclei) in the lungs of mice exposed to cigarette smoke (Figure 1B-C) compared to air-exposed 
animals (Figure 1A). Double stainings against pro-surfactant-protein C (Figure 1B, alveolar epithelial cells identified as blue pro-
surfactant-protein C+ cells) or CD45 (Figure 1C, inflammatory cells identified as blue CD45+ cells) and TUNEL-staining (Fig-
ure 1B-C, dark brown nuclei) demonstrating apoptosis of both structural and inflammatory cells (own unpublished data).
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Schematic representation of different pathways involved in apoptosis Figure 2
Schematic representation of different pathways involved in apoptosis. Extrinsic pathway: 1.  Ligand-
death-receptor pathway (green): death factors such as Fas ligand (FasL) and tumour necrosis factor (TNF) trigger apopto-
sis by binding on 'death receptors' such as Fas and Tumour Necrosis Factor Receptor 1 (TNFR1). FasL may be solubilized to 
sFasL by matrix metalloproteinases (MMP's). The death receptors recruit procaspase-8 by means of an adaptor protein, Fas 
associated death domain protein (FADD). After cleavage the mature caspase-8 then directly activates caspase-3 or cleaves Bid. 
Truncated Bid (tBid) interacts with Bax and Bak. A pore is formed in the outer mitochondrial membrane through which cyto-
chrome c (Cyt C) is released. 2. Cytolytic  effector  cell pathway (orange): cytotoxic T cells can release granzyme 
B and perforin, a pore-forming protein. Granzyme B activates caspase-3 through cleavage. It can also cleave caspase-8. 3. 
Growth factor depletion pathway (red): deprivation of survival factors triggers Cyt C release through activation 
of Bax and Bak. Intrinsic pathway: 4.  Mitochondrial pathway (grey): mitochondria release cytochrome c (Cyt C) 
in response to stress. Together with apoptotic protease activating factor-1 (Apaf-1) and procaspase-9, Cyt C will form the 
apoptosome complex. This results in the proteolytic activation of the procaspase. Mature caspase-9 can then proteolytically 
activate caspase-3 and other executioner caspases. 5. Endoplasmatic  reticulum pathway (blue): the ER can also 
induce apoptosis as a reaction to stress. It might do so by stimulating the mitochondrial pathway or by directly targeting the 
nucleus. In mice both caspase-7 and -12 are linked to this pathway. These different initiation pathways converge further down-
stream into activation of caspase-3. The effector caspase-3 cleaves ICAD (inhibitor of CAD) and releases it from CAD (cas-
pase-activated DNAase). CAD translocates from the cytoplasm to the nucleus and can now act as active endonuclease and 
fragment DNA.
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(CAD) from its inhibitor (ICAD) with DNA fragmenta-
tion as a consequence [10]. This pathway is called the
receptor mediated extrinsic pathway (Figure 2). Impor-
tantly, caspase-8 can also cleave the pro-apoptotic Bid
[11], which then, through interaction with Bax and Bak,
translocates to the mitochondria and causes the release of
cytochrome C (see below). [12].
A second pathway, the mitochondrial intrinsic pathway,
responds to physical and chemical stress signals by the
release of cytochrome C from mitochondria. As a conse-
quence, cytochrome C, apoptotic protease activating fac-
tor-1 (Apaf-1) and caspase-9 form the apoptosome. [13-
15], resulting in the activation of caspase-9 which then
activates caspase-3 and initiates the execution of apopto-
sis [16].
Finally, in the endoplasmatic reticulum pathway, caspase-
12 is activated in response to stress signals such as
hypoxia. [17,18]. In addition to these caspase-dependent
pathways, it has been shown that noncaspase proteases
can process and activate caspases directly (eg activation of
caspase-3 by granzyme B) [19]. Moreover, the deprivation
of survival signals such as growth factors can also induce
apoptosis by mitochondrial release of cytochrome C.
[20,21].
While apoptosis is a tightly regulated active mechanism
leading to programmed cell death, cell necrosis is a rather
uncontrolled process, which is accidental and in which
the cell has no active role [22]. As a consequence, apopto-
sis seems to be a process that can be modulated to main-
tain cell viability, while necrosis is difficult to prevent.
Apoptosis is critical for the maintenance of normal tissue
homeostasis and is in equilibrium with proliferation and
differentiation. There is increasing evidence that distur-
bance of the balance between apoptosis and proliferation
in lung tissue contributes to the pathogenesis of COPD. A
limited number of descriptive studies in human subjects
suggest a possible role for apoptosis in COPD, while an
increasing number of experimental studies in animal
models of COPD provides more insight into the associa-
tion between cigarette smoking, apoptosis and the devel-
opment of emphysema.
Studies on human subjects
Apoptosis in human lung: ex vivo/in vitro
Several groups studied the role of apoptosis in the patho-
genesis of COPD in human subjects, mostly by using lung
tissue sections from COPD patients and controls (Table
1). Segura-Valdez et al described an increase in endothe-
lial cell apoptosis in lung tissue sections from COPD
patients compared to controls. Although less frequently,
apoptotic alveolar epithelial cells, interstitial cells and
inflammatory cells (neutrophils and lymphocytes) were
also described in the lungs of COPD patients, while this
was not the case in control subjects [23].
Imai and colleagues described an increase in apoptotic
cells (alveolar epithelial cells, endothelial cells and mes-
enchymal cells) in emphysematous lung tissue, as well as
an increase in the activated subunits of caspase-3 (an
important caspase in the execution of downstream events
in apoptosis). Moreover, expression of the pro-apoptotic
proteins Bax and Bad was detected in emphysema
patients, while this was not the case in controls. The anti-
Table 1: Overview of studies on apoptosis in human lung.
Reference Patients COPD defined by Controls Increased Apoptosis in 
patients
Increased 
Proliferation in 
patients
Segura-Valdez [23] Chronic 
Bronchitis 
Emphysema
-Medical history
-Pulmonary Function
-Histology/CT
-Male individuals who died 
from other causes than lung 
diseases smoking status 
unknown
-endothelial cells
-alveolar epithelial cells
-interstitial cells
-inflammatory cells
NA
Majo [27] Emphysema -Pulmonary Function
-Histology
-Never smokers
-Smokers without emphysema
-No difference between 
groups
NA
Kasahara [28] Emphysema -Pulmonary Function Non smokers -alveolar epithelial cells NA
-Histology/CT -Smokers without airway 
obstruction
-endothelial cells
Yokohori [25] Emphysema -Pulmonary Function
-Histology
-Asymptomatic smokers
-Asymptomatic nonsmokers
-alveolar epithelial cells type II alveolar epithelial 
cells type II
Imai [24] Emphysema -Pulmonary Function
-Histology
-accidental death victims 
unused donor lungs for LTX
-Smoking status unknown
-alveolar epithelial cells
-endothelial cells
-mesenchymal cells
Increased (cell 
type not specified)
Hodge [26] COPD -Medical history
-Pulmonary Function
-Never smokers -airway epithelial cells 
(obtained by BAL)
-BAL T-cells
NA
BAL = bronchoalveolar lavage; CT = computed tomography; LTX = lung transplantation; NA = not availableRespiratory Research 2006, 7:53 http://respiratory-research.com/content/7/1/53
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apoptotic protein Bcl-2 was not detected in either normal
or emphysematous lung tissue. Interestingly, increased
cell proliferation was found in emphysematous lungs
[24].
Other groups described similar findings, with an increase
in both apoptosis and proliferation of alveolar wall cells
in patients with emphysema compared to smokers with-
out COPD and non-smokers [25]. Hodge et al described
an increase in apoptosis of alveolar epithelial cells and T-
cells from bronchial brushings and bronchoalveolar lav-
age in COPD patients compared to non-smoking con-
trols. [26]. This increase in apoptosis in COPD patients
persisted despite smoking cessation.
Others, on the contrary, did not find a significant differ-
ence in apoptotic alveolar wall cells in the lungs from
smokers without emphysema compared to smokers with
emphysema. [27]. However, in this study, apoptosis in
smokers showed a bilinear relationship with the amount
smoked: the apoptotic index decreased in smokers with-
out emphysema to a minimum at 40 pack year, then
increasing sharply as the pack year increased in smokers
with emphysema. Interesting findings were obtained by
Kasahara et al. These authors demonstrated an increase in
apoptotic epithelial and endothelial alveolar septal cells
in emphysematous lungs compared to non-smokers,
smokers and primary pulmonary hypertension patients.
[28]. Moreover, expression of VEGF and VEGF R2 protein
and mRNA was significantly reduced in emphysema. The
authors hypothesized that this decrease of endothelial cell
maintenance factors, leading to endothelial alveolar sep-
tal death, may be part of the pathogenesis of emphysema.
Recent data from other groups support this finding, by
demonstrating that VEGF levels in induced sputum from
COPD patients decreased with severity of COPD. [29].
However, while VEGF signalling may be required for the
maintenance of the alveolar structures, the 936 C/T poly-
morphism of the VEGF gene (associated with lower VEGF
plasma levels) was not associated with the development
of COPD [30].
Altogether, several studies in human COPD patients
describe an increase in apoptosis, especially in structural
cells in the lung (Table 1). However, some points should
be taken into consideration when interpreting these data.
First, not all studies have studied changes in lung cell pro-
liferation in addition to apoptosis. As mentioned above,
in physiologic circumstances, apoptosis is in balance with
processes such as proliferation and differentiation. As a
consequence, when studying the role of apoptosis in dis-
eases such as COPD, it is recommendable to evaluate
changes in proliferation as well. By doing so, this will
allow to discriminate between a net increase in apoptosis
(not counterbalanced by an increase in proliferation and
leading to the loss of structural lung cells and tissue) and
an equal increase in both apoptosis and proliferation
(where the loss of structural cells by apoptosis is pre-
vented by the regeneration of structural cells in the lung).
By using this approach, Calabrese and colleagues recently
demonstrated that there was a significant increase in
apoptotic alveolar epithelial cells in end-stage emphy-
sema (particularly in emphysema due to α1-antitrypsin
deficiency), while there was no difference in proliferation
of alveolar septal cells between emphysema patients and
controls [31].
Second, in some of these studies, the control groups used
consisted of non-smokers or of smokers with significantly
less pack years of cigarette smoking compared to the
COPD groups. Strictly speaking, one cannot exclude the
possibility that the increase in apoptosis of structural cells
is only related to cigarette smoking per se, rather than
being an event that is specifically associated with the
development of COPD. The ideal situation would be to
compare COPD patients with heavy smokers who did not
develop COPD. Another confounding factor could be the
difference in treatment between patients. Most of the
studies discussed above do not discriminate between
COPD patients that are treated with inhaled corticoster-
oids and those who are not. It has been demonstrated that
corticosteroids induce apoptosis of airway epithelial cells
and eosinophils in asthma. [32]. No such data are availa-
ble for COPD, but these findings underscore the impor-
tance of taking into account the use of inhaled steroids
when examining apoptosis in the airways of COPD
patients.
Thirdly, there are important differences between the dif-
ferent studies regarding the patient population: some
groups identified COPD patients by pulmonary function
tests, while others studied mainly emphysema patients, as
defined by the use of radiologic or histological data. From
these studies, it is unclear whether apoptosis is an under-
lying disease mechanism only for the development of
emphysema, or on the contrary, if it is also involved in the
disease process of COPD patients without emphysema
(and with predominantly bronchiolitis).
Finally, while most groups studied apoptosis of structural
cells, it would be interesting to evaluate changes in apop-
tosis of inflammatory cells in the lungs of COPD patients
as well. It has been suggested that chronic inflammation
in the airways might result from reduced apoptosis of
inflammatory cells, with accumulation of inflammatory
cells and sustained inflammation as a consequence [33].
Apoptosis outside the lungs
COPD is currently regarded as a multi-component disease
with systemic manifestations in addition to local pulmo-Respiratory Research 2006, 7:53 http://respiratory-research.com/content/7/1/53
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nary inflammation [34]. The lung is of course the princi-
pal organ affected by the disease, but the pulmonary
manifestations of the disease are often accompanied by
systemic abnormalities. This seems to be the case for the
disturbance of the balance between apoptosis and regen-
eration too: while apoptosis of structural lung cells has
been demonstrated in COPD patients, several groups
described alterations in apoptosis or apoptotic signals in
the systemic circulation or in skeletal muscles from COPD
patients.
An increased propensity of peripheral blood T cells in
COPD to undergo apoptosis has been described [35]. This
was accompanied by upregulation of several mediators
involved in the induction of T cell apoptosis, such as TNF-
α/TNFR1, Fas and TGFR. The authors hypothesized that
increased rates of T cell apoptosis result in unbalanced
homeostasis, defective clearance mechanisms and perpet-
uation of the inflammatory response.
Takabatake and colleagues described significantly higher
TNF-α and sTNF-R55 and R75 levels in the circulation of
COPD patients, while serum levels of soluble Fas ligand
(sFas-L), an inducer of apoptosis, and plasma levels of the
soluble Fas receptor (sFas), an inhibitor of apoptosis, were
not increased in COPD patients. [36].
Others described a significant increase in sFas in plasma
from severe COPD patients compared to patients with
mild or moderate COPD, while sFas-L was within normal
limits in all groups. [37].
Peripheral muscle weakness, due to muscle atrophy, is
commonly observed in COPD patients. [38,39]. A possi-
ble mechanism of this muscle wasting could be a decrease
in the number of muscle fibres resulting from activation
of apoptotic pathways. It has been reported that skeletal
muscle apoptosis is increased in patients with COPD hav-
ing a low body mass index (BMI) compared to COPD
patients with normal BMI and to healthy volunteers and
is associated with a lower exercise capacity [40]. Oste-
oporosis is another systemic manifestation of COPD [41].
The precise mechanisms involved are unknown and it is
unclear if apoptosis contributes to the development of
osteoporosis in COPD patients. In summary, a limited
number of studies investigated changes in apoptosis out-
side the lung in COPD patients. The relevance of these
findings in the development of COPD is unknown. Future
studies will need to investigate in more detail the relation
between apoptosis in- and outside the lung in COPD and
the importance of apoptosis in the development of sys-
temic manifestations in the course of the disease.
Animal models of COPD and emphysema
When interpreting data obtained from animal models of
COPD, it is important to keep in mind that the develop-
ment of emphysematous lesions in the lungs of cigarette
smoke exposed mice is strain dependent. [42,43]. DBA/2
mice, for example, develop patchy emphysema in
response to cigarette smoke faster than C57Bl/6J mice.
Additionally, in DBA/2 mice, the development of emphy-
sema is preceded by the appearance of apoptotic cells in
areas with a low signal for VEGF-R2 [43], while this is
much less the case for C57Bl/6J mice.
Moreover, animal models of COPD often do not repre-
sent all characteristics of the disease as it occurs in
humans. The current view on the pathogenesis of COPD
is that cigarette smoke induces the recruitment of inflam-
matory cells, which then release reactive oxygen species
and proteolytic enzymes, causing the degradation of lung
matrix and the death of structural cells. However, in sev-
eral animal models of COPD, development of emphy-
sema was observed despite a remarkable lack of
pulmonary inflammation. These studies demonstrated
that, at least in animal models, apoptosis of alveolar wall
or endothelial cells is sufficient to cause pulmonary
emphysema, even without the accumulation of inflam-
matory cells. In those studies, emphysema was induced by
directly targeting the alveolar cells [44], or by inactivating
VEGFR [45-47] or VEGF [48].
The relationship between VEGF, endothelial cell apopto-
sis and emphysema has first been described by Kasahara
and colleagues [45]. These authors demonstrated in a rat
model that blocking of the VEGF receptor induced alveo-
lar cell apoptosis and led to enlargement of the airspaces.
Moreover, treatment with a caspase inhibitor prevented
septal cell apoptosis and emphysema development in
response to the blocking of VEGF receptor.
Other groups showed that cathepsin S-dependent epithe-
lial cell apoptosis is a critical event in the pathogenesis of
IFN-γ induced emphysema [49]. Using this model, it was
recently shown that IFN-γ is a potent activator of the
extrinsic/death receptor and intrinsic/mitochondrial
apoptosis pathways and that these activation events are
partially CCR5 dependent [50].
Aoshiba and colleagues demonstrated that intratracheal
administration of active caspase-3 resulted in epithelial
apoptosis, enhanced elastolytic activity in BAL and the
development of emphysematous changes in mice [44].
Recently, Petrache et al reported that intratracheal instilla-
tion of ceramide, a highly regulated sphingolipid second
messenger, triggers apoptosis of alveolar epithelial and
endothelial cells and induced airspace enlargement inRespiratory Research 2006, 7:53 http://respiratory-research.com/content/7/1/53
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mice [47]. Moreover, increased lung ceramide levels were
detected in the lungs of emphysema patients, suggesting
that ceramide upregulation might be an important patho-
genetic element in the development of emphysema. This
was the first study to describe the involvement of a non-
protein mediator of apoptosis in the pathogenesis of
emphysema.
Others have suggested that humoral- and CD4+ cell-
dependent mechanisms can lead to alveolar septal cell
apoptosis and the development of emphysema [51].
Intraperitoneal injection of endothelial cells led to the
production of antibodies against endothelial cells, influx
of CD4+ T cells in the lung, alveolar septal apoptosis, acti-
vation of matrix metalloproteinases and the development
of emphysema.
Apoptosis and interaction with other pathogenetic 
mechanisms in COPD
As mentioned before, several disease mechanisms are
involved in the development of COPD: inflammation,
proteinase/anti-proteinase imbalance and oxidative
stress. Apoptosis interacts with all of these pathways, add-
ing to the complexity of the disease (Figure 3).
Apoptosis and inflammation
Several groups demonstrated that, at least in animal mod-
els, apoptosis of alveolar wall or endothelial cells is suffi-
cient to cause pulmonary emphysema, even without the
Interaction of apoptosis with other pathogenetic mechanisms in COPD, including inflammation, oxidative stress and protease/ anti-proteinase imbalance Figure 3
Interaction of apoptosis with other pathogenetic mechanisms in COPD, including inflammation, oxidative 
stress and protease/anti-proteinase imbalance. 1. Neutrophil elastase (NE) cleaves the phosphatidylserine receptor on 
macrophages, resulting in impaired clearance of apoptotic cells and sustained inflammation [54]. 2. Cytotoxic CD8+ T-cells 
cause apoptosis of alveolar epithelial cells through the release of perforins and granzyme-B [57,58]. 3. Degradation of the base-
ment membrane (BM) by matrix metalloproteinases (MMPs) leads to loss of survival signals and induces apoptosis of epithelial 
cells [60]. 4. Apoptosis may also be affected by direct proteolysis of death-inducing signals. It has been shown that MMP-7 
sheds and activates Fas ligand (FasL) that is produced by epithelial cells, thereby mediating apoptosis [62]. 5. Oxidative stress 
could lead to a reduction of Vascular Endothelial Growth Factor (VEGF) levels, resulting in apoptosis of alveolar endothelial 
cells [29]. NE: neutrophil elastase; BM: basement membrane; MMPs: matrix metalloproteinases; TIMP: tissue inhibitor of metal-
loproteinase; α1-AT: α1-anti-trypsin; FasL: Fas ligand; VEGF: vascular endothelial growth factor.
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accumulation of inflammatory cells. However, in the
lungs of COPD patients, there is an impressive influx of
inflammatory cells and interactions between inflamma-
tory and apoptotic mechanisms most probably take place.
Alveolar macrophages from patients with COPD are less
effective in phagocytosing apoptotic airway epithelial
cells compared to controls [51]. This might be mediated
by the presence of activated numbers of neutrophils in
COPD. [52,53]. It has been shown that neutrophil
elastase cleaves the phosphatidylserine receptor on mac-
rophages, resulting in impaired clearance of apoptotic
cells and sustained inflammation [54].
In addition to neutrophils and macrophages, there is also
an increase in CD8+ T-lymphocytes in the lungs of COPD
patients. [55,56]. These cytotoxic CD8+ T-cells could
cause apoptosis of alveolar epithelial cells through the
release of perforins, granzyme-B and TNF-α. [57,58].
Apoptosis and proteinase-antiproteinase imbalance
The increase in proteolytic activity in the lungs of COPD
patients might interfere with apoptosis in several ways.
[59]. The basal membrane contains signals for cell sur-
vival and loss of these survival signals (as a consequence
of degradation of the basement membrane by matrix met-
alloproteinases) can induce apoptosis. This process of
apoptosis induced by loss of appropriate cell-matrix con-
tacts (called anoikis) is involved in tissue homeostasis by
maintaining the correct cell number of high turnover epi-
thelial tissues. [60]. Aoshiba and colleagues already sug-
gested that cell-extracellular matrix interactions modulate
apoptosis in bronchial epithelium. [61]. Moreover, they
recently reported elastolytic activity in apoptotic lung epi-
thelial cells in a mouse model of emphysema [44]. Apop-
tosis may also be affected by direct proteolysis of death-
inducing signals. It has been shown that MMP-7 sheds
and activates Fas ligand that is produced by epithelial
cells, thereby mediating apoptosis [62]. Finally, recent
data suggest that MMP-8 has anti-inflammatory effects on
airway inflammation due to a regulation of inflammatory
cell apoptosis [63].
Apoptosis and oxidative stress
In a rat model of emphysema induced by VEGFR block-
ade, Tuder et al demonstrated that apoptosis predomi-
nated in the lung in areas of oxidative stress and that
experimental blockade of apoptosis markedly reduced the
expression of markers of oxidative stress [46]. The admin-
istration of a compound with antioxidant activity pre-
vented the development of alveolar cell apoptosis and
airspace enlargement, suggesting a positive feedback
interaction between oxidative stress and apoptosis. Other
groups have shown that mice with impaired expression of
antioxidant genes have increased numbers of apoptotic
alveolar septal cells (predominantly endothelial and type
II epithelial cells) and develop early and extensive emphy-
sema in response to cigarette smoke. [64]. Recent work
from Kanazawa and colleagues nicely demonstrated ele-
vated oxidative stress levels and a reciprocal reduction of
VEGF levels in induced sputum from COPD patients.
[29]. These changes increased with severity of the disease.
These findings confirm the relationship between oxidant-
antioxidant imbalance and VEGF-dependent homeostasis
of alveolar walls in the lungs of COPD patients. The
authors hypothesize that epithelial cell injury mediated
by oxidative stress induces a decrease in lung VEGF levels,
resulting in the development of COPD. These data clearly
point out that apoptosis is not an isolated event in the
development of COPD and that it interferes with other
underlying disease mechanisms.
Conclusion
An increasing number of data, both from animal models
and studies on human subjects, supports an important
role for apoptosis in the pathogenesis of COPD.
More studies are needed to identify the most important
apoptotic pathways and the caspases involved in the
development of COPD. Moreover, it has to be evaluated if
apoptosis can be used as a therapeutic target to prevent
further deterioration of the disease, which occurs even
after the patients have quit smoking. Finally, as distur-
bance of the balance between apoptosis and regeneration
of structural lung cells seems important in the destruction
of healthy lung tissue, it would be interesting to evaluate
the potential use of stem cell therapy for emphysema.
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VEGF R2: Vascular Endothelial Growth Factor Receptor 2
WHO: World Health Organisation
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